Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|November 17, 2022
Dr. David Silver discusses his experience with HIFU
Author(s)Urology Times staff
Silver also outlines an example of a patient who he would treat with high-intensity focused ultrasound.
Advertisement
In this video, David A. Silver, MD, shares his experience with high-intensity focused ultrasound (HIFU) and describes a sample case. Silver is chief of urology at Maimonides Medical Center in Brooklyn, New York.
Advertisement
Related to this article
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
FDA grants 510(k) clearance to OpenFlo urinary catheter
4
FDA grants fast track designation to VIR-5500 for mCRPC
5